▾ G11 Media Network: | ChannelCity | ImpresaCity | SecurityOpenLab | Italian Channel Awards | Italian Project Awards | Italian Security Awards | ...
InnovationOpenLab

Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy

#Cosylab--Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified cl...

Immagine

LJUBLJANA, Slovenia: #Cosylab--Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared.

"PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it."

Physics-accurate, radiobiologically informed planning

PlanOne™ is built on a GPU-accelerated Monte Carlo dose engine for particle therapy, which serves as the physical foundation for accurate LET calculation and variable RBE modelling*. Clinical teams can plan with confidence and can review plans within a single planning workflow.

Full control over plan robustness

PlanOne™ provides comprehensive user-defined robust optimization, analysis and evaluation. Beyond the worst-case scenario approach, PlanOne™ supports an all-scenario scheme across the full set of user-defined scenarios simultaneously, resulting in treatment plans that reflect physical reality without compromising the plan’s robustness.

One environment. The OIS you already have.

Contouring, planning, and review take place within a single environment, and purpose-built tools support the demands of proton and heavy-ion treatment planning. PlanOne™ integrates with existing oncology information systems, helping preserve established workflows while reducing the need for data migration.

About Cosylab

Cosylab is a software and control systems company headquartered in Ljubljana, Slovenia. With over 20 years of experience and more than 1,000 projects across particle accelerators, radiation therapy devices, and oncology information systems, Cosylab develops complex software for the world's most technically demanding environments. PlanOne™ V1.0 is Cosylab's FDA 510(k) cleared treatment planning system for particle therapy.

PlanOne™ V1.0 is FDA 510(k) cleared. Items marked with * are in preparation for regulatory submission or under development; not yet available for sale and/or clinical use in any market. Market availability is subject to regulatory approval. PlanOne is a trademark of Cosylab d.d., registered in the United States and the European Union.

Fonte: Business Wire

If you liked this article and want to stay up to date with news from InnovationOpenLab.com subscribe to ours Free newsletter.

Related news

Last News

RSA at Cybertech Europe 2024

Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…

Italian Security Awards 2024: G11 Media honours the best of Italian cybersecurity

G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes

How Austria is making its AI ecosystem grow

Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries

Sparkle and Telsy test Quantum Key Distribution in practice

Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…

Most read

Greenstone Biosciences, Inc. and Intel Corp. Launch Strategic Collaboration…

#AIinbiotech--Greenstone Biosciences, Inc. announces a collaboration with Intel Corp. (NASDAQ: INTC) to accelerate AI-enabled drug discovery using Greenstone’s…

Accenture Reports Third-Quarter Fiscal 2026 Results

Accenture (NYSE: ACN) reported financial results for the third quarter of fiscal 2026 ended May 31, 2026. All comparisons are to the third quarter of…

Qnity Powers the Transition from Shrink to Stack with Advanced Packaging…

Qnity Electronics, Inc. (“Qnity”) (NYSE: Q), a premier technology solutions leader across the semiconductor value chain, today announced the launch of…

RebuilderAI Debuts Design-to-Manufacturing AI Agent VRING:ON at VivaTech…

#AIsolution--RebuilderAI, a company specializing in AI-driven design-to-manufacturing automation, unveiled its design-to-manufacturing AI agent, VRING:ON,…

Newsletter signup

Join our mailing list to get weekly updates delivered to your inbox.

Sign me up!